Press Releases

Date Title  
Toggle Summary Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from
Toggle Summary Collegium Reports Third Quarter Financial Results
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019 Cash increased by $6.0 million , to $139.8 million as of September 30, 2018 ; raising
Toggle Summary Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
STOUGHTON, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx ® formulation (Xtampza ® ER),” in the peer-reviewed medical journal, Journal of Opioid Management .
Toggle Summary Collegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and
Toggle Summary Collegium to Present at Upcoming Investor Conference
STOUGHTON, Mass. , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the following investor conference in October: The Cantor Global Healthcare Conference on Tuesday, October 2 nd at 2:50 p.m.
Toggle Summary Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
STOUGHTON, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas .
Toggle Summary Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash balance at end of 2018 anticipated to be at least $135.0 million Conference call scheduled for today at
Toggle Summary Collegium to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass. , July 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Promotion of Scott Dreyer to CCO
CANTON, Mass. , July 10, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the promotion of Scott Dreyer to the position of Executive Vice President and Chief Commercial Officer, effective July 10, 2018 . Mr. Dreyer brings over 25 years of commercial leadership
Toggle Summary Collegium Announces CEO Succession
Joseph Ciaffoni Promoted to CEO and Appointed to Board Michael Heffernan Continues to serve as Chairman of the Board CANTON, Mass. , June 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that Joseph Ciaffoni , Executive Vice President and Chief Operating
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies Global Healthcare Conference on Thursday, June 7 th at 9:30 a.m.
Toggle Summary Collegium Reports First Quarter Financial Results and Provides Corporate Update
Net revenue of $63.7 million , compared to $10.8 million in Q4 2017  Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass.
Toggle Summary Collegium to Present at the Deutsche Bank Health Care Conference
CANTON, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston .
Toggle Summary Collegium to Host Conference Call to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
CANTON, Mass. , April 20, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
CANTON, Mass. , April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco .
Toggle Summary Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
CANTON, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018 . Ms.
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March: The Oppenheimer & Company 28 th Annual Healthcare Conference on Wednesday, March 21 st at 9:10 a.m.
Toggle Summary Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded product portfolio by licensing rights to commercialize Nucynta franchise Revenue growth and strong balance sheet provide cash runway into 2020 Conference call
Toggle Summary Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Closing of Agreement to License Rights to Commercialize Nucynta Franchise
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing commercial infrastructure CANTON, Mass. , Jan.
Toggle Summary Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
CANTON, Mass. , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will be hosting investor meetings at the Guggenheim Securities 5 th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel
Toggle Summary Collegium to License Rights to Commercialize Nucynta Franchise
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing commercial infrastructure Conference call scheduled for Tuesday, December 5 th at 8:30
Toggle Summary Collegium to Present at the 29th Annual Piper Jaffray Healthcare Conference
CANTON, Mass. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that senior management will participate in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference at 2:30pm ET on Tuesday, November 28, 2017 in New York City .
Toggle Summary Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Xtampza ® ER prescriptions grow by 49% in the third quarter FDA Approval of sNDA, including Comparative OxyContin Data Strong balance sheet provides cash runway into mid-2019 Conference call scheduled for today at 4:30 p.m. ET CANTON, Mass. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium
Toggle Summary Collegium Receives FDA Approval for sNDA for Xtampza® ER
Comparative OxyContin Data and Oral Human Abuse Deterrent Claim Added to Label CANTON, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the U.S. Food and Drug Administration ( FDA ) approved its Supplemental New Drug Application (sNDA) to
Toggle Summary Collegium Notified that the FDA Will Not Meet PDUFA Goal Date for sNDA for Xtampza® ER
CANTON, Mass. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the U.S. Food and Drug Administration ( FDA ) will not meet the prescription drug user fee act (PDUFA) date for  its Supplemental New Drug Application (sNDA) to enhance the label for
Toggle Summary Collegium to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2017 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in September: The 19 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 11 th at 12:05 p.m.
Toggle Summary Collegium Announces Scientific Presentations at PAINWeek 2017 Meeting
CANTON, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2017 on September 7th in Las Vegas .
Toggle Summary Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Collegium strengthens leadership team with key additions to executive team and Board of Directors Xtampza ER prescriptions grow by 34% in the second quarter Xtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2036 Well capitalized with $111.2 million in cash
Toggle Summary Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass. , July 18, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids
CANTON, Mass. , June 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza ® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 2017 International Conference on Opioids taking place
Toggle Summary Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass. , June 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza ® ER to its Medicare Part D formularies.  Effective June 1, 2017 ,
Toggle Summary Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer
CANTON, Mass. , May 30, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Joseph Ciaffoni to the newly created position of Executive Vice President and Chief Operating Officer, effective May 31, 2017 .
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , May 23, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m.
Toggle Summary Collegium Reports First Quarter Financial Results and Provides Corporate Update
Xtampza ® ER prescribed by more than 3,000 physicians since commercial launch Xtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2030 Well capitalized with $129.6 million in cash and cash equivalents Conference call scheduled for today at 4:30 p.m.
Toggle Summary Collegium to Host Conference Call to Discuss First Quarter 2017 Financial Results and Provide Corporate Update
CANTON, Mass. , May 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
CANTON, Mass. , April 20, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42 nd Annual Deutsche Bank Healthcare Conference in Boston . The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the
Toggle Summary Collegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy
CANTON, Mass. , April 04, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced it has appointed Steven Passik , PhD, as Vice President of Scientific Affairs, Education and Policy, effective, April 3, 2017 . “We are excited to announce the addition of Steve to the
Toggle Summary Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients
CANTON, Mass. , April 03, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a large national managed care organization with more than 3 million Medicare Part D lives has added Xtampza ® ER to its Medicare Part D formularies.  Effective April 1, 2017 ,
Toggle Summary Collegium to Present at the 16th Annual Needham Healthcare Conference
CANTON, Mass. , March 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 16 th Annual Needham Healthcare Conference in New York City . The presentation will take place at 10:40 a.m. ET on Wednesday, April 5, 2017 at the Westin New
Toggle Summary Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting
CANTON, Mass. , March 16, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza ® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the 33 rd Annual American Academy of Pain Medicine Meeting
Toggle Summary Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Xtampza ® ER prescribed by more than 2,400 physicians since commercial launch ONSOLIS ® patent issued that extends patent protection until 2027 Well capitalized with $153.2 million in cash and cash equivalents CANTON, Mass. , March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.
Toggle Summary Collegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update
CANTON, Mass. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER
CANTON, Mass. , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from an oral human abuse potential clinical trial, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of Xtampza ® ER
Toggle Summary Collegium Announces that Xtampza ER is Available on Express Scripts’ Standard Formularies
CANTON, Mass., December 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it has finalized its contract with Express Scripts, the largest pharmacy benefits management (PBM) in the United States. Pursuant to the contract, Xtampza ER is available on
Toggle Summary Collegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares
CANTON, Mass. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the underwriters for its public offering of 5,000,000 shares of its common stock at $16.00 per share have exercised in full their option to purchase an additional 750,000 shares of common
Toggle Summary Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal
CANTON, Mass. , Nov. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that an independent review of Xtampza ® ER has been published in the peer-reviewed medical journal, Drugs .  The review is titled “Oxycodone DETERx ® ER Capsules: A Review in Severe,
Toggle Summary Collegium to Present at Upcoming Investor Conferences
CANTON, Mass. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in November: The Jefferies London Healthcare Conference on Thursday, November 17th at 12:40 p.m.
Toggle Summary Collegium Reports Third Quarter Financial Results and Provides Corporate Update
Broadened Xtampza ER market access with commitments from large commercial payers Submitted Supplemental New Drug Application to the FDA Submitted New Drug Submission to Health Canada CANTON, Mass. , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.
Toggle Summary Collegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Prices Public Offering of $80 million of Common Stock
CANTON, Mass. , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share.
Toggle Summary Collegium Announces Proposed Public Offering of Common Stock
CANTON, Mass. , Oct. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are being sold by Collegium.  In addition, Collegium has granted the
Toggle Summary Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER
Comparative data vs OxyContin to support label change CANTON, Mass. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration ( FDA ) to enhance the label
Toggle Summary Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass. , Oct. 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the submission of a New Drug Submission (NDS) to Health Canada seeking marketing approval of Xtampza ® ER (oxycodone extended-release), an abuse-deterrent, extended-release opioid, for the
Toggle Summary Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
CANTON, Mass. , Sept. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx ® (Xtampza ® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology .
Toggle Summary Review of Xtampza® ER Published in The Journal of the American Medical Association
CANTON, Mass. , Sept. 09, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an independent review of Xtampza ® ER in The Journal of the American Medical Association (JAMA) .  The review titled, “A New Abuse-Deterrent Opioid–Xtampza ER”, was
Toggle Summary Collegium to Present at the BioCentury NewsMakers Conference
CANTON, Mass. , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at BioCentury’s 23 rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 10:30 a.m.
Toggle Summary Collegium Announces the Launch of OpioidIQ
OpioidIQ encourages responsible opioid prescribing and provides educational tools designed to prevent abuse and misuse of opioids CANTON, Mass. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announces the launch of OpioidIQ, an online educational tool to assist
Toggle Summary Collegium Announces Scientific Presentations at PAINWeek 2016 Meeting
CANTON, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on Xtampza ® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2016 on September 8 th in Las Vegas .
Toggle Summary Collegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER
CANTON, Mass. , Aug. 16, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “An Abuse-Deterrent, Microsphere-in-Capsule Formulation of Extended-Release Oxycodone: Alternative Modes of Administration to Facilitate Pain Management in Patients with
Toggle Summary Collegium Reports Second Quarter Financial Results and Provides Corporate Update
Received FDA approval for Xtampza ® ER, Company’s lead opioid analgesic with abuse-deterrent properties Announced U.S. commercial launch of Xtampza ER Reported positive results from a clinical study comparing effect of physical manipulation of Xtampza ER with the abuse-deterrent version of
Toggle Summary Collegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Receives European Patent Allowance Covering Xtampza® ER
CANTON, Mass. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL), a specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic pain and other diseases, announced that the European Patent Office has
Toggle Summary Collegium to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
CANTON, Mass. , July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time .  The conference will be held at Le Parker Meridian
Toggle Summary Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year
CANTON, Mass. , June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan , received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England . This year marks the 30th anniversary of the EY Entrepreneur of the Year Award
Toggle Summary Collegium Announces Positive Topline Results for Hydrocodone DETERx® Clinical Study
Results demonstrate utility of the DETERx technology platform for hydrocodone as a second abuse-deterrent opioid candidate CANTON, Mass. , June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating
Toggle Summary Collegium Announces Commercial Launch of Xtampza® ER
New Extended-Release Opioid with Abuse-Deterrent Properties CANTON, Mass. , June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza ® ER (oxycodone) extended-release (ER) capsules in the United States .
Toggle Summary Collegium Announces Election of John A. Fallon, M.D. to Board of Directors
CANTON, Mass. , June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon , M.D. to the Board of Directors. "John’s broad-based payer, managed care and physician group practice management experience will be of great value to
Toggle Summary Collegium Announces Poster Presentations for Xtampza™ ER at the International Conference on Opioids
CANTON, Mass. , June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on Opioids , which
Toggle Summary Collegium to Present at Jefferies and William Blair Conferences
CANTON, Mass. , June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference , New York , June 7 th at 10 a.m.
Toggle Summary Collegium Hosting Investor Day Event on May 25, 2016
CANTON, Mass. , May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25 th at the St. Regis Hotel in New York City (2 East 55 th Street). The meeting will commence at 10:00am ET .  Parties interested in attending the event can Click
Toggle Summary Collegium Licenses the U.S. rights to ONSOLIS® from BioDelivery Sciences
Breakthrough cancer pain product added to the portfolio CANTON, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS ® (fentanyl buccal soluble film) from BioDelivery Sciences
Toggle Summary Collegium Announces Poster Presentations for Xtampza™ ER at American Pain Society Meeting
CANTON, Mass. , May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, in an elderly population at the American Pain Society
Toggle Summary Collegium Reports First Quarter Financial Results and Provides Corporate Update
CANTON, Mass. , May 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2016 and provided a corporate update.  “The beginning of this year marked a major milestone for Collegium as we received FDA approval for our
Toggle Summary Collegium Announces Positive Topline Results of Comparative Clinical Trial Evaluating the Effect of Crushing Xtampza™ ER Compared with OxyContin®
CANTON, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a comparative clinical trial evaluating the effect of physical manipulation by crushing of Xtampza™ ER (oxycodone extended-release capsules) compared with the
Toggle Summary Collegium to Host Conference Call to Discuss First Quarter 2016 Financial Results and Provide Corporate Update
CANTON, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 4:30 p.m. Eastern Time .  The Company will discuss its financial results and provide a
Toggle Summary Collegium Receives FDA Approval for Xtampza™ ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain
CANTON, Mass. , April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration ( FDA ) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain
Toggle Summary Collegium to Present at the 15th Annual Needham Healthcare Conference
CANTON, Mass. , April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan , the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City . The presentation will take place at 1:40 p.m.
Toggle Summary Collegium Announces Publication of Data on the Durability of Pain Relief with Xtampza ER
CANTON, Mass. , April 07, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of an analysis of the duration of effect of Xtampza™ ER administered every 12 hours during the Double-blind Maintenance Phase of a multicenter, 12-week clinical study. 
Toggle Summary Collegium Reports 2015 Financial Results and Provides Corporate Update
CANTON, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its 2015 financial results and provided a corporate update.  “Over the last few months, we made significant progress to advance Xtampza™ ER closer to market launch upon final FDA
Toggle Summary Collegium to Host Conference Call to Discuss 2015 Financial Results and Provide Corporate Update
CANTON, Mass. , March 10, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET .  The Company will discuss its financial results for 2015 and provide a
Toggle Summary Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
CANTON, Mass. , March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza ® ER compared to other marketed opioid analgesics in peer-reviewed Journal of
Toggle Summary Collegium Announces Favorable Judgment by the District Court of Massachusetts
CANTON, Mass. , Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P. , The P.F. Laboratories, Inc.
Toggle Summary Collegium Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza™ ER CANTON, Mass. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs" was issued by the
Toggle Summary Collegium Provides Litigation Update
CANTON, Mass. , Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On February 1, 2016 , the U.S. Court of Appeals for the Federal Circuit rendered its decision to uphold a
Toggle Summary Collegium Appoints Ted Schroeder to Board of Directors
CANTON, Mass. , Jan. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led specialty pharmaceutical company Cadence Pharmaceuticals from its founding until its acquisition by
Toggle Summary Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx®
Second Clinical Candidate to Leverage DETERx Technology Platform CANTON, Mass. , Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the Company’s investigational new drug (IND) application to
Toggle Summary Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock
CANTON, Mass. , Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price to the public of $20.00 per share, before underwriting discounts and commissions.
Toggle Summary Collegium Announces Publication of Nasal Human Abuse Potential Study in American Academy of Pain Medicine
CANTON, Mass. , Dec. 16, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the intranasal human abuse potential of Xtampza™ ER (oxycodone) extended-release capsules. The publication is titled “A Randomized, Double-Blind,
Toggle Summary Collegium to Present at the 27th Annual Piper Jaffray Healthcare Conference
CANTON, Mass. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan , the Company's Chairman and CEO, will present at the 27 th Annual Piper Jaffray Healthcare Conference in New York City .
Toggle Summary Collegium Reports Third Quarter Financial Results and Provides Corporate Update
CANTON, Mass. , Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update. "During the last few months, Collegium achieved a number of important milestones in moving Xtampza™ ER
Toggle Summary Collegium to Host Conference Call to Discuss Q3 Financial Results and Provide Corporate Update
CANTON, Mass. , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 12, 2015 at 8:00 a.m. ET . The Company will discuss its financial results for the third quarter of
Toggle Summary Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass. , Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the United States Food and Drug Administration ( FDA ) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules
Toggle Summary Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
CANTON, Mass. , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration ( FDA ) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza™ ER (oxycodone)
Toggle Summary Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass. , Sept. 11, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration ( FDA ) voted
Toggle Summary Collegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek
CANTON, Mass. , Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza™ ER, an abuse-deterrent, extended-release oral formulation of oxycodone, at PAINWeek 2015, taking place
Toggle Summary Collegium Publishes Data From Xtampza(TM) ER Phase 3 Clinical Trial in the Journal PAIN
CANTON, Mass. , Aug. 24, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the Phase 3 clinical trial of Xtampza™ ER (oxycodone extended-release capsules). The study is titled "A phase 3, multi-center, randomized, double-blind,
Toggle Summary Collegium Reports Second Quarter Financial Results and Provides Corporate Update
CANTON, Mass. , Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update. Michael Heffernan , Collegium's Chairman and CEO, stated, " During the second quarter, Collegium
Toggle Summary Collegium to Host Conference Call to Discuss Financial Results and Provide Corporate Update
CANTON, Mass. , Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13, 2015 at 8:00 a.m. ET . The Company will discuss its financial results for the second quarter of
Toggle Summary Collegium Announces FDA Advisory Committee Meeting for Xtampza(TM) ER, an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass. , Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
Toggle Summary Collegium Added to Russell 2000(R), 3000(R) and Global Indexes
CANTON, Mass. , July 6, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place on June 26, 2015 .
Toggle Summary Collegium Expands Leadership Team With Vice President of Regulatory Affairs and Quality Assurance
CANTON, Mass. , July 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that John (Jack) Weet, Ph.D., has joined the company as its Vice President of Regulatory Affairs and Quality Assurance. Dr. Weet will oversee Collegium's Regulatory Affairs and Quality
Toggle Summary Collegium Announces Publication of "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," in Pain Medicine
CANTON, Mass. , June 25, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of a comparative clinical trial titled "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with
Toggle Summary Collegium to Present Xtampza ER(TM) Oral Human Abuse Potential Data at the College on Problems of Drug Dependence 77th Annual Meeting
CANTON, Mass. , June 15, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the presentation of a scientific poster at the College on Problems of Drug Dependence 77th Annual Meeting, held at the Arizona Biltmore in Phoenix, AZ from June 13 to June 18 .
Toggle Summary Collegium Announces Issuance of U.S. Patent Covering DETERx(R) - an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza ER(TM) CANTON, Mass. , June 8, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,044,398 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled,
Toggle Summary Collegium Expands Commercial Organization With Key Appointments
CANTON, Mass. , June 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the addition of Barry Duke as Executive Vice President and Chief Commercial Officer. In addition to Mr. Duke, Mary Ogle joined as Vice President of Marketing and Timothy Hermes as Vice
Toggle Summary Collegium to Present at the Jefferies 2015 Global Healthcare Conference
CANTON, Mass. , May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan , will present at the Jefferies 2015 Healthcare Conference in New York City . The presentation is scheduled for Monday, June 1, 2015
Toggle Summary Collegium Pharmaceutical Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
CANTON, Mass. , May 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions, including
Toggle Summary Collegium Pharmaceutical Announces Pricing of Its Initial Public Offering
CANTON, Mass. , May 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. , (Nasdaq:COLL) today announced the pricing of its initial public offering of 5,800,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions.
Toggle Summary Collegium Pharmaceutical to Present Xtampza ER™ Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting
Canton, MA – March 17, 2015 – Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company’s completed Phase III clinical trial that evaluated the efficacy and safety of its lead drug candidate, Xtampza ER ™, an abuse-deterrent, extended-release analgesic for chronic pain.
Toggle Summary Collegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of its Lead Abuse-Deterrent Product Candidate
Funding follows NDA acceptance of Xtampza ER ™ in February 2015 Canton, MA – March 10, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today
Toggle Summary Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Xtampza ER ™ utilizes the DETERx Technology Platform Canton, MA – February 26, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that
Toggle Summary Collegium Pharmaceutical Announces FDA Acceptance for Filing of NDA for Xtampza ER™ (oxycodone extended-release capsules), an Abuse-Deterrent Analgesic for Chronic Pain
Canton, MA – February 12, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that the U.S.
Toggle Summary Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to Its Board of Directors
Management team significantly strengthened by adding financial expertise Canton, MA – February 9, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases,
Toggle Summary “Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain with Dysphagia (CPD),” Published in Pain Practice
Clinical study demonstrates that the Xtampza ER ™ ER (oxycodone extended-release) drug release profile is maintained when sprinkled onto food Canton, MA – January 15, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for
Toggle Summary Collegium Pharmaceutical Submits New Drug Application for Xtampza™ ER (oxycodone extended-release); Its Abuse-Deterrent, Extended-Release Analgesic for the Treatment of Chronic Pain
Canton, MA – December 15, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has filed a New Drug Application ( NDA ) with the U.S. Food & Drug Administration ( FDA ) seeking
Toggle Summary Collegium Pharmaceutical’s CEO to Present at the 26th Annual Piper Jaffray 2014 Healthcare Conference in New York on December 3, 2014
Canton, MA – November 25, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO , Michael Heffernan, will present the Company’s corporate overview on
Toggle Summary Collegium Pharmaceutical Releases Positive Top-Line Results of Oral Human Abuse Potential (HAP) Study with Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Product
Primary endpoint met in oral abuse potential study Canton, MA – November 17, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced positive top-line results from its second human abuse
Toggle Summary “Patients with Chronic Pain and Dysphagia (CPD): Unmet Medical Need and Pharmacologic Treatment Options,” Published in Current Medical Research and Opinion
Canton, MA – October 7, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of “Patients with Chronic Pain and Dysphagia ( CPD ): Unmet Medical Need and Pharmacologic
Toggle Summary Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Canton, MA – September 23, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent No. 8,840,928 has been issued by the U.S. Patent and Trademark Office ( USPTO ). The issued patent covers the DETERx ® technology platform.
Toggle Summary Collegium Pharmaceutical Announces Publication of Abuse-Deterrent Data on Oxycodone DETERx® in Journal of Opioid Management
Study results support the novel abuse-deterrent properties of Oxycodone DETERx ® Canton, MA – August 20, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of the following
Toggle Summary Collegium Pharmaceutical Awarded Grant from the NIH to Advance Development of Oxymorphone DETERx®, an Abuse-Deterrent, Extended-Release Product for Chronic Pain
NIH grant supports development of Collegium’s second drug candidate utilizing the DETERx ® technology platform Canton, MA – August 7, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has been awarded a Phase I, Fast Track Small Business Innovation
Toggle Summary Collegium Pharmaceutical Announces Positive Top-Line Data from Phase III Study of Oxycodone DETERx®, its Abuse-Deterrent, Extended-Release Product for Chronic Pain
Data Supports 2014 NDA Filing Canton, MA – August 6, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced positive top-line results from its pivotal Phase 3 study of the company’s investigational analgesic Oxycodone DETERx ® that studied the treatment of
Toggle Summary Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Opioid Product
Canton, MA – July 2, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent No. 8,758,813 has been issued by the U.S. Patent and Trademark Office ( USPTO ). The patent relates to Collegium’s Oxycodone DETERx ® formulation and contains claims that
Toggle Summary Collegium Announces Poster Presentations for Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Analgesic at the 2014 International Conference on Opioids
Canton, MA – June 5, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of two scientific posters at the 2014 International Conference on Opioids ( ICOO ), held in Boston,
Toggle Summary Collegium Pharmaceutical Advances Development Program for Hydrocodone DETERx®, an Abuse-Deterrent, Extended-Release Analgesic for the Treatment of Chronic Pain
Third Opioid Candidate Utilizing the DETERx® Technology Canton, MA – May 29, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has identified candidates for its Hydrocodone DETERx ®
Toggle Summary Collegium Pharmaceutical to Present at the Jefferies 2014 Global Healthcare Conference in New York on June 3, 2014
Canton, MA – May 27, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO , Michael Heffernan, will present the Company’s corporate overview on Tuesday,
Toggle Summary Collegium Pharmaceutical’s CEO to Present at the UBS 2014 Global Healthcare Conference in New York on May 21, 2014
Canton, MA – May 13, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO , Michael Heffernan, will present the Company’s corporate overview on Wednesday,
Toggle Summary Collegium Pharmaceutical Announces Successful Pre-NDA Meeting with FDA for Oxycodone DETERx®, its Extended-Release, Abuse-Deterrent Product for the Treatment of Chronic Pain
Canton, MA – April 29, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has successfully concluded its pre-New Drug Application ( NDA ) meeting with the U.S.
Toggle Summary Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx® Compared with OxyContin®
Oxycodone DETERx ® exhibited superior crush resistance Canton, MA – April 2, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced positive topline results from a clinical study evaluating the
Toggle Summary Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Canton, MA – March 19, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent Application No. 12/965,572 has been allowed for issuance as a new patent by the U.S. Patent and Trademark Office ( USPTO ).
Toggle Summary Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx®, its Lead Abuse-Deterrent Development Program
Top-line results anticipated in second quarter 2014 Canton, MA – February 4, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of patient enrollment in the pivotal Phase 3